Featured Articles
-
Vial Adapter Transfer Device Compatibility With Cell Therapies
7/25/2025
Needles and syringes are commonly used to retrieve cell therapies from vials, posing the risk of needle stick injury. Explore the suitability of needle-free polycarbonate transfer devices.
-
Vial Adapter Considerations For Cell And Gene Therapy Applications
4/21/2025
Review features that need to be considered to choose a vial adapter for cell and gene therapy drug products and a case study where vial adapter transfer devices have been used to extract lentiviruses.
-
Vial Containment Systems For Gene Therapies: Series Summary
4/9/2025
Proactively understanding containment system performance can streamline development and accelerate market delivery. Review comparative data for CZ-based systems and traditional glass or polypropylene options.
-
Vial Containment Systems For Gene Therapies: Recovery Of Viral Vectors
4/9/2025
Vial containment systems were evaluated for maintenance of virus transducability after storage at ultralow temperature. All vectors showed equivalent or better function compared to standard systems.
-
Vial Containment Systems For Gene Therapies: Container Closure Integrity
4/9/2025
Maintenance of CCI at ultra-low temperature is a necessity for a gene therapy vial containment system. Systems comprising cyclic olefin polymer vials and elastomer stoppers with a barrier film were evaluated over time.
-
Vial Containment Systems For Gene Therapies: Materials Considerations
4/9/2025
Storage of a vial containment system at ultra-low temperature presents risk not encountered at ambient temperature. Review material advantages of cyclic olefin polymer vials.
-
Vial Containment Systems: Interactions With Glass, Polymer, And Elastomer
4/9/2025
Explore how certain vials and elastomer stoppers provide better protection than corresponding borosilicate glass vials and elastomer stoppers without a barrier film.
-
Vial Containment Systems For Gene Therapies: Series Overview
4/9/2025
This chapter discusses basics of gene therapies, including function, anticipated growth rates, companies involved and estimates of therapies in pipeline, and examples of commercial products and indications.
-
FAQs On The Revised EU GMP Annex 1: Volume 2
3/5/2025
Review the implementation of a holistic Contamination Control Strategy (CCS). Discover four key considerations for assessing component readiness: product, process, protection, and proof.
-
FAQs On The Revised EU GMP Annex 1: Volume 1
3/5/2025
The revised GMP Annex 1 guidelines emphasize quality risk management, enhanced environmental monitoring, and data integrity, which aim to minimize contamination and ensure patient safety.